WallStreetZenWallStreetZen

NASDAQ: CERS
Cerus Corp Stock Forecast, Predictions & Price Target

Analyst price target for CERS

Based on 2 analysts offering 12 month price targets for Cerus Corp.
Min Forecast
$2.50+32.28%
Avg Forecast
$2.75+45.5%
Max Forecast
$3.00+58.73%

Should I buy or sell CERS stock?

Based on 2 analysts offering ratings for Cerus Corp.
Buy
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CERS stock forecasts and price targets.

CERS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-07
lockedlocked$00.00+00.00%2024-03-06

1 of 1

Forecast return on equity

Is CERS forecast to generate an efficient return?
Company
N/A
Industry
-0.02%
Market
21.01%

Forecast return on assets

Is CERS forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.02%

CERS revenue forecast

What is CERS's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$173.3M-7.23%
Avg 2 year Forecast
$195.2M+4.5%
Avg 3 year Forecast
$216.8M+16.06%
CERS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CERS revenue growth forecast

How is CERS forecast to perform vs Medical Devices companies and vs the US market?
Company
2.2%
Industry
8.37%
Market
9.6%
CERS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CERS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CERS vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
CERS$1.89$2.75+45.50%Buy
AXGN$8.07$10.67+32.18%Strong Buy
LUNG$9.27$15.40+66.13%Strong Buy
VMD$9.43N/AN/A
NPCE$13.20$17.00+28.79%Strong Buy

Cerus Stock Forecast FAQ

Is Cerus Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CERS) stock is to Buy CERS stock.

Out of 2 analysts, 1 (50%) are recommending CERS as a Strong Buy, 0 (0%) are recommending CERS as a Buy, 1 (50%) are recommending CERS as a Hold, 0 (0%) are recommending CERS as a Sell, and 0 (0%) are recommending CERS as a Strong Sell.

If you're new to stock investing, here's how to buy Cerus stock.

What is CERS's revenue growth forecast for 2024-2026?

(NASDAQ: CERS) Cerus's forecast annual revenue growth rate of 2.2% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.6%.

Cerus's revenue in 2024 is $186,797,000.On average, 1 Wall Street analysts forecast CERS's revenue for 2024 to be $31,416,296,243, with the lowest CERS revenue forecast at $31,416,296,243, and the highest CERS revenue forecast at $31,416,296,243. On average, 1 Wall Street analysts forecast CERS's revenue for 2025 to be $35,386,387,920, with the lowest CERS revenue forecast at $35,386,387,920, and the highest CERS revenue forecast at $35,386,387,920.

In 2026, CERS is forecast to generate $39,302,094,780 in revenue, with the lowest revenue forecast at $39,302,094,780 and the highest revenue forecast at $39,302,094,780.

What is CERS's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: CERS) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of -0.02%.

What is CERS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CERS price target, the average CERS price target is $2.75, with the highest CERS stock price forecast at $3.00 and the lowest CERS stock price forecast at $2.50.

On average, Wall Street analysts predict that Cerus's share price could reach $2.75 by Mar 7, 2025. The average Cerus stock price prediction forecasts a potential upside of 45.5% from the current CERS share price of $1.89.

What is CERS's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: CERS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.